Global market entry for medical devices depends on decisions made long before regulatory submission. As regulatory expectations continue to shift due to AI and technological expansions in global markets, it’s more important than ever to ensure that clinical trials are set up for long-term success. Clinical study design, data strategy and regulatory alignment must come together early to avoid delays later. By aligning clinical data, endpoints and patient populations early, medical device companies can reduce risk and accelerate market access.

Authored by Kenneth Rayl, Nima Akhlaghi, Michelle Bulliard, Hamidreza Alidousti and Chava Zibman, this insight brief shows how to build a clinical approach that supports regulatory approvals across regions, with a focus on US, Europe and Japan